Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation

Transplant Immunology

Volumn 27, Issue 1, 2012, Pages 59-62

  Remberger, Mats ^a   Persson, Magnus ^a   Mattsson, Jonas ^a   Gustafsson, Britt ^a   Uhlin, Michael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ATG; GVHD; HSCT; Rabbit IgG; UCB

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; THYMOCYTE ANTIBODY; TREOSULFAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MALE; MESENCHYMAL STROMA CELL; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PUVA; RADIATION DOSE; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84864542382     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.06.003     Document Type: Article

References (25)

1. Hows J., Bradley B.A., Gore S., Downie T., Howard M., Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) study. Bone Marrow Transplant 1993, 12:371-380.
2. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
3. Remberger M., Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009, 15:996-999.
4. Regan J.F., Lyonnais C., Campell K., Smith L.V., Buelow R. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol 2001, 9:29-36.
5. Blume K.G., Kopecky K.J., Henslee-Downey J.P., Forman S.J., Stiff P.J., LeMaistre C.F., et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bonemarrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993, 81:2187-2193.
6. Uzunel M., Remberger M., Sairafi D., Hassan Z., Mattsson J., Omazic B., et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006, 82:913-919.
7. Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
8. Casper J., Knauf W., Kiefer T., Wolff D., Steiner B., Hammer U., et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004, 103:725-731.
9. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
10. Remberger M., Svahn B.-M., Hentschke P., Löfgren C., Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 24:823-830.
11. Ringdén O., Remberger M., Persson U., Ljungman P., Aldener A., Andström E., et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995, 15:619-625.
12. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. (11Review) (11 refs). Bone Marrow Transplant 1995, 15:825-828.
13. Gooley T., Leisenring W., Crowley J., Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
14. Bacigalupo A., Lamparelli T., Bruzzi P., Guidi S., Alessandrino P.E., di Bartolomeo P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
15. Mohty M., Bay J.O., Faucher C., Choufi B., Bilger K., Tournilhac O., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003, 102:470-476.
16. Call S.K., Kasow K.A., Barfield R., Madden R., Leung W., Horwitz E., et al. Total and active rabbit antithymocyte globulin (rATG; thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bonemarrow transplantation. Biol BloodMarrow Transplant 2009, 15:274-278.
17. Eiermann T.H., Lambrecht P., Zander A.R. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999, 23:779-781.
18. +-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:609-618.
19. Regan J.F., Lyonnais C., Campbell K., Smith L.V., Buelow R. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol 2001, 9:29-36.
20. Seidel M.G., Fritsch G., Matthes-Martin S., Lawitschka A., Lion T., Pötschger U., et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005, 27:532-536.
21. Waller E.K., Langston A.A., Lonial S., Cherry J., Somani J., Allen A.J., et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003, 9:460-471.
22. Podgorny P., Ugarte-Torres A., Liu Y., Williamson T., Russel J., Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010, 16:915-926.
23. Okas M., Gertow J., Uzunel M., Karlsson H., Westgren M., Kärre K., et al. Clinical expansion of cord blood-derived T-cells for use as donor lymphocyte infusion after cord blood transplantation. J Immunother 2010, 33:96-105.
24. Bacigalupo A., Lamparelli T., Gualandi F., Bregante S., Raiola A.M., Di Grazia C., et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002, 8:656-661.
25. Kröger N., Zabelina T., Kruger W., Renges H., Stute N., Rischewski J., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002, 29:683-689.